Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Beta Bionics, Inc. ( (BBNX) ) has provided an announcement.
On May 21, 2026, Beta Bionics announced it plans to fully commercialize Mint, its patch insulin pump in development, by the end of the second quarter of 2027, contingent on FDA clearance as an alternate controller enabled insulin pump. The company said the revised timeline reflects initial FDA feedback on its 510(k) submission and progress in scaling manufacturing, and it expects production capacity to meet demand at launch.
Mint, which stands for Mini Insulin Therapy, is designed to pair with Beta Bionics’ FDA-approved interoperable automated glycemic controller and leading continuous glucose monitors, offering smartphone control, a three-day wear time with a grace period and a two-piece architecture aimed at reducing waste. By positioning Mint alongside its existing iLet platform and leveraging established pharmacy channel access, Beta Bionics is seeking to expand form-factor choice for its users and strengthen its competitive standing in the growing patch pump market.
The most recent analyst rating on (BBNX) stock is a Hold with a $11.00 price target. To see the full list of analyst forecasts on Beta Bionics, Inc. stock, see the BBNX Stock Forecast page.
Spark’s Take on BBNX Stock
According to Spark, TipRanks’ AI Analyst, BBNX is a Neutral.
The score is held back primarily by persistent losses and heavy cash burn despite strong revenue growth and healthy gross margins, alongside a weak technical setup with the stock below major moving averages. The latest earnings call provides a partial offset via raised guidance, improving gross margin outlook, and solid liquidity, but elevated operating expense intensity and FDA remediation risks remain meaningful.
To see Spark’s full report on BBNX stock, click here.
More about Beta Bionics, Inc.
Beta Bionics, Inc. is a commercial-stage medical device company focused on advanced diabetes management solutions for insulin-requiring people with diabetes. The company designs, develops and commercializes devices such as the FDA-cleared iLet Bionic Pancreas, which autonomously determines insulin doses using adaptive closed-loop algorithms to improve outcomes and simplify treatment.
Average Trading Volume: 1,021,054
Technical Sentiment Signal: Sell
Current Market Cap: $450.5M
Learn more about BBNX stock on TipRanks’ Stock Analysis page.